Ipsogen has announced a non-exclusive license agreement with Quest Diagnostics for the use of the Jak2 V617F mutation in Quest Diagnostics's laboratory developed tests.
Additional terms were not disclosed.
8 Oct 2008 by Ipsogen
Ipsogen has announced a non-exclusive license agreement with Quest Diagnostics for the use of the Jak2 V617F mutation in Quest Diagnostics's laboratory developed tests.
Additional terms were not disclosed.
